Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus

Lupus

Volumn 21, Issue 11, 2012, Pages 1172-1177

  Bador, K M ^a   Samsudin, Intan Nureslyna ^b   Hussin, S ^a   Gafor, A H A ^a  

^a DEPARTMENT OF PHARMACOLOGY   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Bacterial infection; Predictive values; Procalcitonin; SLE

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN; CALCITONIN; PROTEIN PRECURSOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOMATION; BACTERIAL INFECTION; BACTERIUM CULTURE; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST; DISEASE ACTIVITY; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOASSAY; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; BLOOD; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ADULT; AUTOMATION; BACTERIAL INFECTIONS; C-REACTIVE PROTEIN; CALCITONIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOASSAY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84873105653     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312450085     Document Type: Article

References (23)

1. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients. Medicine 1999; 78: 167–175.
2. ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenburg CG. C-reactive protein levels during disease exacerbation and infection in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990; 17: 1642–1648.
3. Roy S, Tan KT. Pyrexia and normal C-reactive protein (CRP) in patients with systemic lupus erythematosus: always consider the possibility of infection in febrile patients with systemic lupus erythematosus regardless of CRP levels. Rheumatology 2001; 40: 349–350.
4. Williams RC, Harmon ME, Burlingame R, Du Clos TW. Studies of serum CRP in SLE. J Rheumatol 2005; 32: 454–461.
5. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. PCT for early diagnosis and differentiation of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 2000; 26: S148–152.
6. Suprin E, Camus C, Gacouin A, et al. PCT: A valuable indicator of sepsis in medical ICU? Intensive Care Med 2000; 26: 1232–1238.
7. Sierra R. C-reactive protein and procalcitonin as markers of infection, inflammatory response and sepsis. Clin Pulm Med 2007; 12: 127–139.
8. Delevaux I, Andre M, Colombier M, et al. Can PCT measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 2003; 62: 337–340.
9. Assicot M, Gendrel D, Carsin H, Raymond J, Gullbaud J, Bohuon C. High serum PCT concentrations in patients with sepsis and infection. Lancet 1993; 341: 515–518.
10. Levy M, Fink M, Marshal J, et al. SCCM/ESICM/ACCP/ATS/ SIS International sepsis definitions conference. Crit Care Med 2001; 31: 1250–1256.
11. Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schuttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 1998; 24: 680–684.
12. Wanner GA, Keel M, Steckholzer U, Beier W, Stocker R, Ertel W. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 2000; 28: 950–957.
13. Carsin H, Assicot M, Feger F, et al. Evolution and significance of circulating PCT levels compared with IL-6, TNFα and endotoxin levels early after thermal injury. Burns 1997; 23: 218–224.
14. Leonhardt U, Werner M, Engelmann L. Procalcitonin in autoimmune disease with sepsis. Crit Care 2001; 5: S25 (abstract P52).
15. Shin KC, Lee YJ, Kwang SW, et al. Serum PCT measurements for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis 2001; 60: 988 (letter).
16. Saavedra PG, Velasquez M, Uribe O, Vasquez G, Ramirez L. PCT in the differential diagnosis of fever in patients with SLE. Ann Rheum Dis 2006; 65: 358 (abstract FRI0238).
17. Ho W-L, Lan J-L, Chen D-Y, Chen Y-H, Huang W-N, Hsieh T-Y. Procalcitonin may be a potential biomarker for distinguishing bacterial infection from disease activity in febrile patients with systemic lupus erythematosus. Formosan Journal of Rheumatology 2009; 23: 52–58.
18. Lanoix JP, Bourgeois AM, Schmidt J, et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus 2010; 1–6.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725 (letter).
20. Urowitz MB, Gladman DD. Measures of disease activity and damage in SLE. Clin Rheumatol 1998; 12: 405–413.
21. Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of PCT for differentiation between activity of systemic autoimmune disease (SLE/systemic antineutrophil cytoplasmic antibody associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40: 1250–1256.
22. Quintana G, Medina Y, Rojas C, et al. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheum 2008; 14: 138–142.
23. Ng WL, Chu CM, Wu AKL, Cheng VCC, Yuen KY. Lymphopenia at presentation is associated with increased risk of infections among patients with systemic lupus erythematosus. QJM 2006; 99: 37–47.